Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAIN-MET01 study of glumetinib in MET-altered NSCLC brain metastases
ChiCTR2400080739Phase 4Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Feb 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of glumetinib and furmonertinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Beijing Tiantan Hospital. Primary endpoints: Progression-free survival and Intracranial progression-free survival. Started Feb 2024; status: recruiting.
02
Drugs
glumetinibfurmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400080739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080739.